Psychosomatic Symptoms in Terminally Ill Cancer Patients and Its Relation With Using Complementary and Alternative Medicines: A Cross-Sectional Study in Southeast Iran.
alternative and complementary medicines
cancer
physical symptoms
psychological symptoms
quality of life
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
02
2022
accepted:
20
04
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
epublish
Résumé
Cancer patients face various problems and complications, which they address through various complementary and alternative medicines (CAM). The aim of this study was to investigate the relationship between CAM and psychosomatic symptoms in terminally ill cancer patients. This cross-sectional study was performed on 221 terminally ill cancer patients (based on metastatic stage and according to the physicin diagnosis) in southeastern Iran. Convenience sampling was used to select terminally ill cancer patients. Using questionnaires like the demographic and clinical information questionnaire, Edmonton Symptom Assessment Scale (ESAS), Hospital Anxiety and Depression Scale (HADS), CAM questionnaire and satisfaction with the use of CAM, the researcher was able to compile a comprehensive picture of the population. The mean age of the participants was 51.66 ± 13.34 years. The majority of the samples were female, married, educated, and unemployed. The mean score for the physical symptoms of the participants according to ESAS was 22.25 ± 17.57 which was less than the midpoint of the scale (the possible score of ESAS was 0-100). Only 2.7% ( Patients with cancer have a relatively low level of psychosomatic symptoms, and the primary reason for using CAM was to relieve stress and anxiety associated with cancer and treat it. However, psychosomatic symptoms were the same for CAM and non-CAM users. Because so many people with cancer use CAM, future studies should look into why and how CAM is used.
Sections du résumé
Background
UNASSIGNED
Cancer patients face various problems and complications, which they address through various complementary and alternative medicines (CAM). The aim of this study was to investigate the relationship between CAM and psychosomatic symptoms in terminally ill cancer patients.
Methods
UNASSIGNED
This cross-sectional study was performed on 221 terminally ill cancer patients (based on metastatic stage and according to the physicin diagnosis) in southeastern Iran. Convenience sampling was used to select terminally ill cancer patients. Using questionnaires like the demographic and clinical information questionnaire, Edmonton Symptom Assessment Scale (ESAS), Hospital Anxiety and Depression Scale (HADS), CAM questionnaire and satisfaction with the use of CAM, the researcher was able to compile a comprehensive picture of the population.
Results
UNASSIGNED
The mean age of the participants was 51.66 ± 13.34 years. The majority of the samples were female, married, educated, and unemployed. The mean score for the physical symptoms of the participants according to ESAS was 22.25 ± 17.57 which was less than the midpoint of the scale (the possible score of ESAS was 0-100). Only 2.7% (
Conclusion
UNASSIGNED
Patients with cancer have a relatively low level of psychosomatic symptoms, and the primary reason for using CAM was to relieve stress and anxiety associated with cancer and treat it. However, psychosomatic symptoms were the same for CAM and non-CAM users. Because so many people with cancer use CAM, future studies should look into why and how CAM is used.
Identifiants
pubmed: 35656344
doi: 10.3389/fpsyt.2022.871917
pmc: PMC9152133
doi:
Types de publication
Journal Article
Langues
eng
Pagination
871917Informations de copyright
Copyright © 2022 Dehghan, Hoseini and Zakeri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cancer Surviv. 2016 Oct;10(5):850-64
pubmed: 26920872
Curr Psychol. 2021;40(12):6324-6332
pubmed: 33746463
Phytother Res. 2021 Sep;35(9):5143-5153
pubmed: 34164855
Ann Oncol. 2013 Apr;24(4):895-900
pubmed: 23175625
J Affect Disord. 2018 Nov;240:105-112
pubmed: 30059936
Case Rep Cardiol. 2020 Oct 1;2020:6061958
pubmed: 33062339
Integr Cancer Ther. 2005 Mar;4(1):14-20
pubmed: 15695473
Tumori. 2008 Nov-Dec;94(6):833-7
pubmed: 19267101
Saudi Pharm J. 2018 Mar;26(3):416-421
pubmed: 29556133
Psychiatry Investig. 2021 May;18(5):443-452
pubmed: 34053210
J Gastrointest Cancer. 2021 Jun;52(2):499-507
pubmed: 33950368
Qual Life Res. 2011 Jun;20(5):683-90
pubmed: 21080084
J Oncol Pharm Pract. 2022 Jun;28(4):827-835
pubmed: 33861657
BMC Complement Med Ther. 2021 Jun 8;21(1):167
pubmed: 34103037
Cancer Invest. 2022 Jan;40(1):26-34
pubmed: 34634986
Cancer Invest. 2022 Feb;40(2):115-123
pubmed: 34699294
J Oncol. 2020 Dec 10;2020:3289521
pubmed: 33381176
J Affect Disord. 2011 Dec;135(1-3):184-92
pubmed: 21864913
Integr Cancer Ther. 2021 Jan-Dec;20:1534735420988343
pubmed: 33543655
Case Rep Med. 2021 Apr 17;2021:6668722
pubmed: 33959162
J Pharm Bioallied Sci. 2016 Jan-Mar;8(1):52-7
pubmed: 26957870
Integr Cancer Ther. 2005 Jun;4(2):187-94
pubmed: 15911931
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Evid Based Complementary Altern Med. 2017 Oct;22(4):731-735
pubmed: 28446027
Lancet Oncol. 2014 Oct;15(11):e471-2
pubmed: 25281463
Support Care Cancer. 2015 Jul;23(7):1979-85
pubmed: 25516212
J Altern Complement Med. 2017 May;23(5):362-369
pubmed: 28453297
ESMO Open. 2020 Oct;5(5):e000970
pubmed: 33097653
Palliat Med. 2009 Dec;23(8):739-53
pubmed: 19825894
Cancer. 2000 May 1;88(9):2164-71
pubmed: 10813730
Int J Health Plann Manage. 2021 Jan;36(1):209-211
pubmed: 32841418
Clin Psychol Rev. 2002 May;22(4):499-524
pubmed: 12094509
J Pain Symptom Manage. 2011 Nov;42(5):691-701
pubmed: 21565460
Integr Cancer Ther. 2018 Sep;17(3):844-853
pubmed: 29629606
Front Endocrinol (Lausanne). 2022 Mar 01;13:798975
pubmed: 35299966
BMC Complement Altern Med. 2011 Nov 25;11:117
pubmed: 22117933
Depress Anxiety. 2009;26(12):1066-85
pubmed: 19957279
BMC Complement Altern Med. 2016 Jul 11;16:204
pubmed: 27400742
J Nerv Ment Dis. 2021 Jul 1;209(7):491-496
pubmed: 33600121
J Evid Based Complementary Altern Med. 2017 Apr;22(2):210-215
pubmed: 26666436
Complement Ther Med. 2017 Aug;33:78-84
pubmed: 28735830
Indian J Palliat Care. 2017 Oct-Dec;23(4):419-424
pubmed: 29123349
J BUON. 2009 Apr-Jun;14(2):265-9
pubmed: 19650177
J Clin Oncol. 2007 Feb 10;25(5):548-54
pubmed: 17290064
Chin J Integr Med. 2018 Aug;24(8):584-590
pubmed: 28028721
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
Cancer Rep (Hoboken). 2021 Oct;4(5):e1378
pubmed: 33742793
Clin Oncol (R Coll Radiol). 2012 Mar;24(2):139-48
pubmed: 21652191
Curr Oncol. 2009 Jan;16(1):55
pubmed: 19229371
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 26811194
Complement Ther Med. 2020 Jun;51:102431
pubmed: 32507442
J Integr Med. 2022 Jan;20(1):45-51
pubmed: 34840104
J Cancer Educ. 2016 Mar;31(1):47-54
pubmed: 25663357